As Ack1 inhibitors have been proven to be of crucial importance to counter the resistance of hormone-dependent tumors, and, importantly, our data showed for the first time that blocking Ack1 could be a new therapeutic approach to overcome drug resistance of EGFR TKI in lung cancer, it is worthwhile to develop novel and selective Ack1 inhibitors in the near future. The gene discussed is TNK2; the disease is lung carcinoma.